Monday, 21st of July 2008 |
CSU 31/2008: FUTURE GLOBAL POLICIES FOR MANAGING POLIOVIRUSES
This article, also available at http://www.ajph.org/cgi/reprint/98/7/1322
reviews the options before governments and international agencies
confronted with the risks and benefits of different polio vaccination
policies.
The authors do not support the expensive switch from OPV to IPV, more and
more accepted in the industrialized world, as a global policy.
Authors' summary is below' full text on the Internet.
Good reading.
BD
'
The Risks, Costs, and Benefits of Possible Future Global Policies for
Managing Polioviruses
Kimberly M. Thompson, ScD, Radboud J. Duintjer Tebbens, PhD, Mark A.
Pallansch, PhD, Olen M. Kew, PhD, Roland W. Sutter, MD, MPH, R. Bruce
Aylward, MD, MPH, Margaret Watkins, MPH, BSN, Howard E. Gary, Jr, PhD,
James Alexander, MD, MEd, Hamid Jafari, MD and Stephen L. Cochi, MD, MPH
Objectives.We assessed the costs, risks, and benefits of possible future
major policy decisions on vaccination, surveillance, response plans, and
containment following global eradication, of wild polioviruses.
Methods.We developed a decision analytic model to estimate the incremental
cost-effectiveness ratios and net benefits of risk management options for
polio for the 20-year period and stratified the world according to income
level to capture important variability between nations.
Results.For low-, lower-middle-, and upper-middle-income groups currently
using oral poliovirus vaccine (OPV), we found that after successful
eradication of wild polioviruses, OPV cessation would save both costs and
lives when compared with continued use of OPV without supplemental
immunization activities. We found cost-effectiveness ratios for switching
from OPV to inactivated poliovirus vaccine to be higher (i.e., less
desirable) than other health investment opportunities, depending on the
actual inactivated poliovirus vaccine costs and assumptions about whether
supplemental immunization activities with OPV would continue.
Conclusions.Eradication promises billions of dollars of net benefits,
although global health policy leaders face difficult choices about future
policies. Until successful eradication and coordination of posteradication
policies, health authorities should continue routine polio vaccination and
supplemental immunization activities.
July 2008, Vol 98, No. 7 | American Journal of Public Health 1322-1330
© 2008 American Public Health Association
Good reading.
BD
Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
Immunization Agenda 2030
Tuesday, 11th of February 2020 |
40560811 |
www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |